Feasibility study of subcutaneous implantable cardioverter-defibrillator after transvenous lead extraction
10.3760/cma.j.cn112148-20250828-00610
- VernacularTitle:静脉导线拔除后植入皮下植入型心律转复除颤器的可行性研究
- Author:
Cuizhen YUAN
1
;
Feng ZE
1
;
Ding LI
1
;
Cuncao WU
1
;
Jinshan HE
1
;
Yi WEI
1
;
Jingliang ZHOU
1
;
Xuebin LI
1
Author Information
1. 北京大学人民医院心内科，北京100044
- Publication Type:Journal Article
- Keywords:
Defibrillators, implantable;
Cardiac implantable electronic device;
Transvenous implantable cardioverter defibrillator;
Subcutaneous implantable cardiove
- From:
Chinese Journal of Cardiology
2025;53(10):1141-1145
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical feasibility of subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation following transvenous lead extraction (TLE).Methods:This was a retrospective study. Consecutive patients who underwent S-ICD implantation at Peking University People′s Hospital between June 2015 and October 2023 were enrolled. Patients were divided into the TLE group and the newly implanted group based on whether they received TLE prior to S-ICD implantation. Baseline characteristics, S-ICD indication, defibrillation threshold test results, complications, and postoperative follow-up data were collected and compared between the two groups.Results:A total of 27 patients were included, aged (49.2±14.2) years, including 19 males. There were 12 patients in the TLE group and 15 in the newly implanted group. Compared with the TLE group, patients in the newly implanted group were younger ((43.3±13.7) years vs. (55.6±12.0) years, P=0.013). The main S-ICD indication in the TLE group was high infection risk (9/12), whereas in the newly implanted group it was younger age (11/15). All patients underwent successful S-ICD implantation, with 18 patients completing defibrillation threshold testing (all successful). Additionally, the TLE group had longer follow-up duration than the newly implanted group (42 (19, 60) months vs. 12 (3, 28) months, P=0.001). No complications or deaths occurred during follow-up, with normal device function in both groups. A total of 17 ventricular tachycardia or fibrillation events were recorded, of which 7 met defibrillation criteria and all received effective therapy. Conclusion:S-ICD demonstrates safety and efficacy as a therapeutic option for patients after TLE, with comparable device functionality and follow-up outcomes to patients with newly implanted S-ICD.
